Literature DB >> 19874705

The Hsp90 chaperone machinery: from structure to drug development.

Ji-Sook Hahn1.   

Abstract

Hsp90, an evolutionarily conserved molecular chaperone, is involved in the folding, stabilization, activation, and assembly of a wide range of 'client' proteins, thus playing a central role in many biological processes. Especially, several oncoproteins act as Hsp90 client proteins and tumor cells require higher Hsp90 activity than normal cells to maintain their malignancy. For this reason, Hsp90 has emerged as a promising target for anti-cancer drug development. It is still largely unknown how Hsp90 can recognize structurally unrelated client proteins. However, recent progress in structural studies on Hsp90 and its interaction with various co-chaperones has broadened our knowledge of how the Hsp90 ATPase activity, which is essential for its chaperone function, is regulated and coupled with the conformational changes of Hsp90 dimer. This review focuses on the roles of various Hsp90 co-chaperones in the regulation of the Hsp90 ATPase cycle, as well as in the selection of client proteins. In addition, the current development of Hsp90 inhibitors based on the structural information will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874705     DOI: 10.5483/bmbrep.2009.42.10.623

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  26 in total

1.  Expression and purification of Src-family kinases for solution NMR studies.

Authors:  Andrea Piserchio; David Cowburn; Ranajeet Ghose
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Gene expression, metabolic regulation and stress tolerance during diapause.

Authors:  Thomas H MacRae
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  Proteasome inhibition-induced downregulation of Akt/GSK-3β pathway contributes to abnormality of tau in hippocampal slice.

Authors:  Min Xie; Ruihong Shi; Ying Pan; Tao Zeng; Qicai Chen; Shaohui Wang; Xiaomei Liao
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

4.  Assessment of placental and maternal stress responses in patients with pregnancy related complications via monitoring of heat shock protein mRNA levels.

Authors:  Ilona Hromadnikova; Lenka Dvorakova; Katerina Kotlabova; Andrea Kestlerova; Lucie Hympanova; Veronika Novotna; Jindrich Doucha; Ladislav Krofta
Journal:  Mol Biol Rep       Date:  2014-10-31       Impact factor: 2.316

5.  Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authors:  Jooeun Bae; Aditya Munshi; Cheng Li; Mehmet Samur; Rao Prabhala; Constantine Mitsiades; Kenneth C Anderson; Nikhil C Munshi
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

6.  Aniline-induced nitrosative stress in rat spleen: proteomic identification of nitrated proteins.

Authors:  Xiuzhen Fan; Jianling Wang; Kizhake V Soman; G A S Ansari; M Firoze Khan
Journal:  Toxicol Appl Pharmacol       Date:  2011-06-15       Impact factor: 4.219

7.  Expression of hsp90 mediates cytoprotective effects in the gastrodermis of planarians.

Authors:  Maria Conte; Maria Emilia Isolani; Paolo Deri; Linda Mannini; Renata Batistoni
Journal:  Cell Stress Chaperones       Date:  2010-08-13       Impact factor: 3.667

8.  Noninvasive imaging of cell death using an Hsp90 ligand.

Authors:  Danielle Park; Anthony S Don; Tania Massamiri; Amol Karwa; Beth Warner; Jan MacDonald; Christine Hemenway; Arati Naik; Kah-Tiong Kuan; Pierre J Dilda; Jason W H Wong; Kevin Camphausen; Lori Chinen; Mary Dyszlewski; Philip J Hogg
Journal:  J Am Chem Soc       Date:  2011-02-15       Impact factor: 15.419

Review 9.  Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

Authors:  S K Kalia; L V Kalia; P J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

10.  The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Authors:  Alexandra Canonici; Zulfiqar Qadir; Neil T Conlon; Denis M Collins; Neil A O'Brien; Naomi Walsh; Alex J Eustace; Norma O'Donovan; John Crown
Journal:  Invest New Drugs       Date:  2018-02-02       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.